Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Free Access

Contrasting Monosymptomatic Patients with Hallucinations and Delusions in First-Episode Psychosis Patients: A Five-Year Longitudinal Follow-Up Study

Evensen J.a, b · Røssberg J.I.a, b · Haahr U.h · ten Velden Hegelstad W.e, f · Joa I.e, f · Johannessen J.O.e, f · Langeveld H.e, f · Larsen T.K.e, f · Melle I.a, b · Opjordsmoen S.a, b · Rund B.R.d · Simonsen E.h · Sundet K.d · Vaglum P.c · Friis S.a, b · McGlashan T.g

Author affiliations

aDivision of Psychiatry, Oslo University Hospital, bInstitute of Psychiatry, cDepartment of Behavioral Sciences in Medicine and dInstitute of Psychology, University of Oslo, Oslo, eRegional Centre for Clinical Research in Psychosis, Psychiatric Clinic, Stavanger University Hospital, Stavanger, and fInstitute of Psychiatry, University of Bergen, Bergen, Norway; gDepartment of Psychiatry, Yale University School of Medicine, Yale Psychiatric Research at Congress Place, New Haven, Conn., USA; hRoskilde Psychiatric University Hospital Fjorden, Roskilde, Denmark

Corresponding Author

Julie Horgen Evensen

Psychiatric Division, Oslo University Hospital, Ullevaal

NO–0407 Oslo (Norway)

Tel. +47 99 41 07 52, Fax +47 22 11 84 23

E-Mail j.h.evensen@medisin.uio.no

Related Articles for ""

Psychopathology 2011;44:90–97

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: The main aim of this study was to identify subgroups of patients characterized by having hallucinations only or delusions only and to examine whether these groups differed with regard to demographic characteristics, clinical characteristics and outcome factors, including suicidality. Methods: Out of 301 consecutively admitted patients with first-episode psychosis, individuals with delusions only (D) and hallucinations only (H) were identified based on Positive and Negative Syndrome Scale (PANSS) items P1 (delusions) and P3 (hallucinations) scores at baseline and through 4 follow-up interviews over 5 years. The subgroups were compared with regard to demographic data, premorbid functioning, duration of untreated psychosis, clinical variables, time to remission and suicidality. Results: Two groups of patients were identified; H (n = 16) and D (n = 106). 179 patients experienced both hallucinations and delusions (dual symptom group). The H group was significantly younger, had a longer duration of untreated psychosis, poorer premorbid function and better insight than the D group. Notably, the H group scored higher on measures of suicidality, and at 5 years follow-up a significantly higher proportion of patients was lost to suicide in this group. The dual symptom group was closer to the D group on significant parameters, including suicidality and suicide rate. Conclusions: Patients with hallucinations only can be separated from patients with delusions only and the subgroups differ with regard to demographical data, clinical variables and notably with regard to suicidality. These findings suggest distinctions in the underlying biological and psychological processes involved in hallucinations and in delusions.

© 2011 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 07, 2009
Accepted: July 29, 2010
Published online: January 13, 2011
Issue release date: January 2011

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 4

ISSN: 0254-4962 (Print)
eISSN: 1423-033X (Online)

For additional information: http://www.karger.com/PSP

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.